Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
QTTB 
Q32 Bio Inc (QTTB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/23/2025: QTTB (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $15
1 Year Target Price $15
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 255.91% | Avg. Invested days 56 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/23/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.32M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 1.34 - 53.17 | Updated Date 10/23/2025 |
52 Weeks Range 1.34 - 53.17 | Updated Date 10/23/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.34 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.95% | Return on Equity (TTM) -491.67% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -10885937 | Price to Sales(TTM) - |
Enterprise Value -10885937 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 12197615 | Shares Floating 5388418 |
Shares Outstanding 12197615 | Shares Floating 5388418 | ||
Percent Insiders 6.54 | Percent Institutions 69.52 |
Upturn AI SWOT
Q32 Bio Inc
Company Overview
History and Background
Q32 Bio Inc. is a clinical stage biotechnology company developing therapeutics to restore immune homeostasis. Founded in 2020, it focuses on modulating the complement system and IL-7 pathways for autoimmune and inflammatory diseases.
Core Business Areas
- Complement Modulation: Developing therapeutics targeting the complement system to treat autoimmune and inflammatory diseases.
- IL-7 Pathway Modulation: Developing therapeutics targeting the IL-7 pathway to treat autoimmune diseases and restore immune homeostasis.
- ADAPT Platform: Utilizing its proprietary ADAPT platform to discover and develop novel therapeutics.
Leadership and Structure
The leadership team includes key executives with experience in immunology, drug development, and business strategy. The organizational structure consists of research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- ADX-914 (Anti-CD86 antibody): A fully human anti-CD86 antibody designed to selectively block the CD86 costimulatory pathway. Currently in clinical trials for autoimmune diseases. Competitors include companies developing similar costimulatory blockade therapies such as abatacept (Orencia) from Bristol Myers Squibb.
- ADX-097 (Complement Inhibitor): A tissue-targeted complement modulator designed to locally inhibit complement activation in diseased tissues. Currently in preclinical development. Competitors include companies developing systemic complement inhibitors such as Alexion Pharmaceuticals (acquired by AstraZeneca).
Market Dynamics
Industry Overview
The autoimmune disease therapeutics market is a large and growing market driven by the high prevalence of autoimmune disorders and the increasing demand for novel therapies. The market is characterized by intense competition and significant unmet medical needs.
Positioning
Q32 Bio is positioned as a developer of novel therapeutics that address the underlying causes of autoimmune diseases by restoring immune homeostasis. Their competitive advantage lies in their ADAPT platform and their focus on complement and IL-7 pathways.
Total Addressable Market (TAM)
The autoimmune disease therapeutics market is estimated to be worth hundreds of billions of dollars. Q32 Bio is targeting specific segments within this market, such as those with high unmet need or those where their therapies have a differentiated profile.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPT platform
- Targeting validated biological pathways (complement, IL-7)
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Clinical stage company with no approved products
- Dependence on successful clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
- High R&D costs
Opportunities
- Successful clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion of product pipeline into new indications
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- BMY
- AZN
- LLY
Competitive Landscape
Q32 Bio faces competition from established pharmaceutical companies and other biotechnology companies developing therapies for autoimmune diseases. Q32 Bio's competitive advantage lies in their novel approach to restoring immune homeostasis and their proprietary ADAPT platform. Disadvantages include being smaller with fewer resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical development programs and expansion of the product pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of products. Analyst estimates vary widely depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing ADX-914 into later-stage clinical trials and expanding the ADAPT platform to identify new drug targets.
Summary
Q32 Bio is an early-stage biotech company with promising technology focused on autoimmune diseases. Its strengths lie in its ADAPT platform and novel targets, but it faces risks common to clinical-stage companies. Successful clinical trials and strategic partnerships will be critical for future success. The company needs to watch out for larger companies and their advancements.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Q32 Bio Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-28 | CEO & Director Ms. Jodie Pope Morrison | ||
Sector Healthcare | Industry Biotechnology | Full time employees 27 | Website https://www.q32bio.com |
Full time employees 27 | Website https://www.q32bio.com | ||
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.